Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study

@inproceedings{Hanefeld2011DoubleblindRM,
  title={Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study},
  author={Markolf Hanefeld and Andreas Pf{\"u}tzner and Thomas Forst and Iris Kleine and Winfried Fuchs},
  booktitle={Cardiovascular diabetology},
  year={2011}
}
BackgroundWe analyzed specific effects of an add-on therapy with pioglitazone compared to metformin and their combination in patients with basal insulin treatment on biomarkers of CV risk.MethodsIn this double-blind, randomized, multicentre, active comparator controlled trial, 121 patients with type 2 diabetes were enrolled. Inclusions: treatment with basal insulin, HbA1C 6.5% - 8.5%, age 30 - 75 years. After glargine therapy over 2 weeks for titration towards FBG ≤ 7.8 mmol/L, patients… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Effect of Circular ANRIL on the Inflammatory Response of Vascular Endothelial Cells in a Rat Model of Coronary Atherosclerosis.

  • Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Clinical practice recommendations2010

PM Ridker, NJ Brown, DE Vaughan, DG Harrison, JL Mehta
  • Diabetes Care
  • 2010